US2014206641A1PendingUtilityA1

Remedy

Assignee: TERADA HIROSHIPriority: Aug 27, 2002Filed: Mar 21, 2014Published: Jul 24, 2014
Est. expiryAug 27, 2022(expired)· nominal 20-yr term from priority
A61P 37/00A61P 37/04A61P 43/00A61P 37/06A61P 31/06A61P 33/02A61P 31/18A61P 29/00A61P 31/04A61P 35/00A61K 31/739A61P 1/04A61K 45/06A61K 31/496A61K 9/1647A61K 35/74A61K 31/00A61K 9/50A61K 47/34A61K 45/00A61K 9/1635Y02A50/30
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

It is intended to provide a remedy for diseases caused by macrophages with dysfunction or mediated by macrophages. Namely, a remedy which activates the phagocytic capacity of macrophages and thus is efficiently incorporated into the macrophages due to the vigorous phagocytosis. As a result, the macrophages with dysfunction are normalized, macrophages infected with a pathogen are exterminated or a pathogen in the infected macrophages is exterminated.

Claims

exact text as granted — not AI-modified
1 - 13 . (canceled) 
     
     
         14 . A method of treating AIDS comprising;
 facilitating a phagocytic activity of macrophages by a lipopolysaccharide to activate the macrophages wherein the macrophages are infected by HIV;   inducing a change of a membrane structure in the macrophages;   inducing a membrane-bound tumor necrosis factor (TNF) in the macrophages, and   inducing cell death of the macrophages.   
     
     
         15 . The method according to  claim 14 , wherein the lipopolysaccharide is derived from  Pantoea agglomerans.    
     
     
         16 . The method according to  claim 14 , wherein the macrophages are MOLT-4 cells infected with HIV.

Join the waitlist — get patent alerts

Track US2014206641A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.